ACCP INFD PRN and Bassam Ghanem push debate on removing routine atypical coverage for non-severe community-acquired pneumonia, pointing to renewed scrutiny of macrolide empiricism.
Time to revisit empiric atypical coverage in non-severe CAP?
Target trial emulation using a propensity-weighted cohort from 68 hospitals in Michigan >66,000 patients:
• No difference in time to clinical stability
Target trial emulation
from 68 hospitals in Michigan >66,000 patients:
No difference in time to clinical stability
Who has made moves to remove routine atypical coverage for your non-severe CAP patients?
Much Ado About Macrolides: Revisiting Empiric Atypical Coverage in Non-severe Community-acquired Pneumonia
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare